Skip to main content
. 2014 Nov;52(11):3863–3868. doi: 10.1128/JCM.01693-14

FIG 2.

FIG 2

sPMCA amplification of BSE-infected brain homogenate spiked into a 100-fold excess of scrapie agent. (A) Representative Western blots from the blind trial depicting duplicate sPMCA analyses of four separate BSE/scrapie agent mixes: lane 1, ovine BSE in ovine scrapie; lane 2, ovine BSE in atypical ovine scrapie; lane 3, classical ovine scrapie only; and lane 4, atypical ovine scrapie only. +S, PK-digested scrapie-infected brain blotting control; M, molecular mass markers (20 and 30 kDa); NEG, 4 negative-control sPMCA amplifications that contained no TSE; +BSE, positive-control amplifications that were spiked with 0.1 μl of 10% ovine BSE-infected brain only. Blots were developed with SHa31 antibody. (B) Representative examples of putative BSE sPMCA-positive samples from the blind trial probed with SHa31 (top) and P4 (bottom). Lanes 1, 3, 5, and 6, ovine BSE agent spiked into classical ovine scrapie; lanes 2 and 4, ovine BSE agent in CH1641 scrapie; lanes 7 and 8, ovine BSE agent in atypical scrapie; and lane 9, caprine BSE agent in caprine scrapie. +B, PK-digested BSE-infected brain blotting control.